Objectives The aim of this study was to examine molecular alterations on the protein level in lesions of oral lichen planus (OLP), oral squamous cell carcinoma (OSCC) and healthy mucosa. Materials and methods Global protein profiling methods based on liquid chromatography coupled to mass spectrometry (LC-MS) were used, with a special emphasis on evaluation of deregulated extracellular matrix molecules expression, as well as on analyses of IG2F and IGFR2 expression in healthy mucosa, OLP and OSCC tissues by comparative semiquantitative immunohistochemistry. Results Mass spectrometry-based proteomics profiling of healthy mucosa, OLP and OSCC tissues (and accompanied histologically unaltered tissues, respectively) identified 55 extracellular matrix proteins. Twenty among identified proteins were common to all groups of samples. Expression of small leucine-rich extracellular matrix proteoglycans lumican and biglycan was found both in OSCC and OLP and they were validated by Western blot analysis as putative biomarkers. A significant increase (p < 0.05) of biglycan expression in OLP-AT group was determined in comparison with OLP-T group, while lumican showed significant upregulation (p < 0.05) in OLP-T and OSCC-T groups vs. adjacent and control tissue groups. Biglycan expression was only determined in OSCC-AT group. Immunohistochemical analysis of IGF2 and IG2FR expression revealed no significant difference among groups of samples. Conclusion/clinical relevance Biglycan and lumican were identified as important pathogenesis biomarkers of OLP that point to its malignant potential.
Introduction
Oral lichen planus (OLP) is a chronic T cell-mediated autoimmune inflammatory mucocutaneous disease that usually affects middle-aged females [1, 2] . It is categorized as a potentially malignant disorder associated with an increased risk of oral cancer [3] , with variable estimated rates ranging from 0 to 5.3% [4] . The association between OLP and oral squamous cell carcinoma (OSCC) has been investigated at the molecular pathophysiological level with modern technologies [5] [6] [7] [8] [9] [10] [11] . It was suggested that chronic inflammation in OLP induces DNA damage, leading to increased cell proliferation and the development of oral cancer [10, 11] .
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Mass spectrometry-based proteomics approach is a valuable tool for identification of novel cellular determinants and molecular mechanisms in many types of cancers, including head and neck cancers [12] . In particular, novel potential oral cancer biomarkers might be exploited in individualized and improved therapeutic management of patients. Such cancer biomarkers might have a prognostic or therapeutic value in the clinical practice. Therefore, the rationale of presented study was to investigate in more details molecular alterations on the protein level in such lesions by use of global protein profiling methods based on liquid chromatography coupled to mass spectrometry (LC-MS) with a special emphasis on evaluation of deregulated extracellular matrix molecules expression, which is known to be of particular importance in pathogenesis of many diseases including tumours. In addition, malignant transformation in many types of cancers, including head and neck cancer, correlates with deregulation of the insulin-like growth factor receptor signalling pathways [13] [14] [15] [16] . This signalization is important in initial steps of malignant transformation of many carcinomas and alternations in the insulin growth factor receptor (IGFR)-mediated cellular signalling pathway are also associated with head and neck cancers [8] [9] [10] [11] [17] [18] [19] [20] [21] . In addition, expression of the insulin-like growth factor receptor 2 (IGF2R) was found to be essential for cytotoxic T cellmediated apoptosis of target cells both in vitro and in vivo conditions which might be important in malignant disease as well [22] . Another factor associated with inflammation that contributes to malignant transformation and tumour growth is a disrupted extracellular matrix (ECM) dynamics and composition that favourizes a tumour-promoting microenvironment [23, 24] . Such ECM changes positively impact extracellular-mediated intracellular signal transduction processes relevant for cell proliferation [25] .
In this paper, we therefore present OLP and OSCC proteomics results, with a particular emphasis on expression analysis of ECM biglycan and lumican and corresponding IGF2R axis status.
Materials and methods

Tissue samples
A total of 62 biopsy samples were analysed by immunohistochemistry, including samples obtained from 24 patients diagnosed with oral lichen planus (collected during surgery on Department of Oral Medicine, School of Dental Medicine, University of Zagreb; OLP group), 20 [26] [27] [28] . Only patients with both clinically and histopathologically confirmed diagnosis of OLP and OSCC were included in the study Exclusion criteria were non-conformation of clinical and histopathological diagnosis or treatment with chemo-or radiotherapy in patients with OSCC before taking the tissue sample, to avoid the effect of therapy on results of tissue analysis. For immunohistochemical analysis, all biopsies were fixed in 10% phosphate buffer formaldehyde and embedded in paraffin blocks. In addition, tissue samples from three patients with both clinically and histopathologically confirmed diagnosis of oral lichen planus, three patients with both clinically and histopathologically confirmed diagnosis of OSCC and three patients with clinically healthy oral mucosa and without previous anamnestic data regarding oral diseases, which were selected after clinical examination, were collected for global proteomic profiling. From each patient with OLP and OSCC, two tissue samples were taken-one from clinically changed mucosa (OLP-T, OLP tissue; OSCC-T, OSCC Table 1 Main clinical and pathological characteristics of patients whose biopsy specimens were used for immunohistochemical analyses. Histological grading of OSCC was determined according to Broder et al. [28] (G1 = well-differentiated tumour, G2 = moderately good differentiated tumour; G3 = poorly differentiated tumour) . Obtained lysates were subjected to sonication with 4 mm probe, power 6 W (MicrosonTM, PGC Scientifics, USA), four times for 10 s. After sonication, 10 μl of nuclease mix (Amersham, USA) was added to the samples and incubated for 1 h at room temperature with gentle agitation on a thermos-shaker (Eppendorf, Germany). Samples were then centrifuged for 45 min at 14,000 rpm and 4°C (Eppendorf, Germany). The supernatants were collected separately and stored at − 80°C. Protein concentrations were determined by use of Qubit™ fluorometric (Invitrogen, USA) quantitation platform. Before measurement of protein concentration, the platform was calibrated with Qubit protein standards (Invitrogen, USA).
Sample preparation procedure for mass spectrometry analyses
For mass spectrometry analysis (LTQ Velos Orbitrap Velos mass spectrometer, Thermo Scientific, San Jose, CA, USA), 15 tissue samples divided in five groups (OSCC-T and matched OSSC-AT group; OLP-T and matched OLP-AT; control group) were prepared according to manufacturer's instructions by use of protein digestion kit RapiGest SF (Waters, USA). Briefly, 50 μg of total proteins was precipitated in four volumes of ice cold acetone at − 20°C overnight for removal of ionic impurities and lipids. After precipitation of proteins, samples were centrifuged for 10 min at 4°C and 14,000 rpm followed by acetone removal and drying out the protein precipitates in a vacuum concentrator (Eppendorf, Germany). To each sample, 50 μl 0.1% working RapiGest SF solution and DTT at 5 mM (Sigma-Aldrich, USA) were added. After incubation of 30 min at 50°C, the samples were cooled to room temperature, and iodoacetamide at final concentration 15 mM was added in a dark chamber for 30 min. Enzymatic digestion of proteins was performed by addition of 5 μl of sequencing grade trypsin at final trypsin concentration of 20 μg/ml (Promega, Madison, WI, USA) to each sample and incubation for 4 h at 37°C. RapiGest SF surfactant (Waters, USA) was hydrolyzed by adding TFA (Sigma-Aldrich, USA) to a final concentration of 0.5% and incubation at 37°C for 35 min. Acid treated samples were then centrifuged for 10 min at 15°C and 14,000 rpm and obtained solutions were transferred to new vials. Aliquots containing 6 μg of proteins (2.5% of the original amount) were desalted by using ZipTip C18 pipette tips (Merck Millipore, Billerica, MA, USA) according to manufacturer recommendations. Peptides were eluted with 10 μl of a 60% acetonitrile containing solution (Sigma-Aldrich, USA) with 0.1% TFA and dried in a vacuum concentrator (Eppendorf, Germany). The samples were re-dissolved in 20 μl of 3% acetonitrile and 0.1% formic acid for the LC-MS analyses.
Nano-LC-MS/MS analysis
Tryptic peptides were fractionated on a 75 μm × 12 cm column containing 3 μm Monitor C18 resin (Orochem Technologies, Inc., Lombard, IL, USA) and having an integrated 10 μm ESI emitter tip (BSelf-Pack^PicoFrit column; New Objective, Woburn, MA, USA). Solvent A was 0.1 M acetic acid in water and solvent B was 0.1 M acetic acid in acetonitrile. Peptides were eluted with a linear acetonitrile gradient (0-70% solvent B over 60 min), operated at 200 nl/ min using an Agilent 1200 HPLC (Agilent Technologies, Santa Clara, CA, USA). The column eluate was introduced directly into the LTQ Velos Orbitrap Velos mass spectrometer (Thermo Scientific, San Jose, CA, USA) with a 1.8-kV ESI voltage. Full MS scans in the m/z range 300-1700 at a nominal resolution of 60,000 were collected in the Orbitrap, followed by data-dependent acquisition of MS/MS spectra for the ten most abundant ions in the LTQ ion trap. Only ions having a charge state ≥ 2 were considered for collisioninduced dissociation. Repeated fragmentation of the same ion was minimized by employing a 30-s dynamic exclusion time.
Protein identification
MS/MS spectra were searched against the human Uniprot protein database (downloaded on April 12, 2014 from 
Western blot analysis
For the Western blot procedure, a total of 50 μg proteins from aforementioned 15 tissue samples divided in five groups (OSCC-T and matched OSSC-AT group; OLP-T and matched OLP-AT; control group) were resolved on 10% SDS polyacrylamide gels using the Mini-protean cell (Bio-Rad, USA). The PVDF membranes (Bio-Rad, USA) were incubated with primary antibodies raised against human lumican (1:1000, rabbit mAb, Abcam, UK) and biglycan (1:1000, rabbit mAb, Abcam, UK) at 4°C overnight, respectively. Secondary antibody linked to anti-rabbit (1:1000, Dako, USA) was used. The signal was visualized by Western Lightning Chemiluminescence Reagent Plus Kit (Perkin Elmer, USA) on the ImageQuant LAS500 (GE Healthcare, USA). As the loading controls (1:1000, α-tubulin, mAb, Sigma-Aldrich, USA; 1:1000, GAPDH, mAb, GeneTex, USA) showed deregulated expression between different groups of samples, the signal intensities of particular bands were normalized with the total protein stain [29, 30] , a robust and reliable approach for semi-quantitative Western blot analysis of protein expression in tissue samples and compared in Quantity One software (Bio-Rad, USA).
Statistical analysis
For determination of differences in lumican relative expression status between control and both OLP (OLP-T and OLP-AT) and OSCC (OSCC-T and OSCC-AT) groups, parametric ANOVA in Microsoft Excel was performed. As biglycan expression was detected only both in OLP-T and OLP-T groups of samples and solely in OSCC-AT group of samples, parametric two-tailed paired t test 
Results
Proteomics profiling
Global proteomics profiling was performed for 15 samples divided in five groups (OSCC-T and matched OSSC-AT group; OLP-T and matched OLP-AT; control group). Obtained data was analysed in Uniprot database (http://uniprot.org) with the emphasis on extracellular matrix proteins. In total, 55 extracellular matrix proteins were found to be expressed in analysed samples (Table 3) with very high confidence, Mowse score > 64 for all charge states, at least three identified peptides per protein, false discovery rate on protein level and peptide estimated at 1%. Comparative analysis of identified extracellular matrix proteins between different groups showed that 20 among identified proteins were common to all groups of samples (Table 3) . Six identified proteins, namely ladinin 1, eukaryotic initiation factor 4A-I, cathepsin D, cofilin-1, laminin subunit beta-3 and protein S100-A9, were unique to OSCC-T group and three identified proteins to OSSC-AT group, namely mimecan, suprabasin and cystatin-A (Table 3 ). In addition, two identified extracellular matrix proteins were unique to OLP-T group, namely tenascin-X and Ras-related C3 botulinum toxin substrate 1, two proteins were unique to OLP-AT group, namely X isoform of 40S ribosomal protein S4 and mitochondrial stress-70 protein, and four proteins were unique to control, namely collagen alpha-1(XII) chain, versican core protein, fibulin-1 and asporin (Table 3) . Furthermore, Uniprot database (http://uniprot. org) search of unique extracellular matrix proteins identified in OSCC-T group showed their functional involvement in a number of cellular processes that contribute to disease progression, such as for example reorganization of the actin cytoskeleton (i.e. cofilin-1), remodelling of extracellular matrix molecules (i.e. laminin subunit beta-3 and cathepsin D), chemokine production (i.e. protein S100-A9) and processing of ribonucleic acids and proteins (eukaryotic initiation factor 4A-I). On the other hand, only two unique extracellular matrix proteins were identified in the OLP-T group, namely tenascin-X and Ras-related C3 botulinum toxin substrate 1, which were both associated with enhanced cellular adhesion on extracellular matrix. Also, mass spectrometry analysis revealed a number of small leucine-rich extracellular matrix proteoglycans, i.e. mimecan, decorin, biglycan and lumican and among them only biglycan was common to OLP-T, OSCC-T and their matched, adjacent tissue samples. Lumican was, on the other side, i d e n t i f i e d i n a l l a na l y s e d g r o u p s of s am p l e s . Aforementioned small leucine-rich proteoglycans were further subjected to semi-quantitative Western blot analysis.
Western blot results
Expression of small leucine-rich extracellular matrix proteoglycans lumican and biglycan was found both in OSCC and OLP and were thus, additionally semi-quantitatively validated by Western blot analysis as putative biomarkers. Chemiluminescent signals for biglycan were detected in OLP-AT, OLP-T and OSCC-T groups while lumican expression was detected in all analysed groups of samples (Fig. 3a) , which was in accordance with results of global proteomics profiling. Also, significant increase (p < 0.05) of biglycan expression in OLP-AT group was determined in comparison with OLP-T group (Fig. 3b) , while lumican showed significant up-regulation (p < 0.05) in OLP-T and OSCC-T groups vs. adjacent and control tissue groups (Fig. 3b) .
Biglycan expression was only determined in OSCC-AT group (Fig. 3b) .
Discussion
New analytical methods are continuously underpinning development of research in the field of malignant disorders. In particular, identification of novel biomarkers, i.e. diagnostic markers, would help clinicians in the diagnostic process, presymptomatic interventions or prediction of treatment response. One interesting discipline for analysis of novel, putative biomarkers is proteomics based on mass spectrometry. In this study therefore, proteomics was used to analyse in more details ECM proteins and proteins related to ECM signalization and that have a well-established role in malignant transformation and invasion of tumour cells. The ECM is the noncellular component present within all tissues and organs. It is composed by a complex mixture of glycoproteins, proteins, proteoglycans and polysaccharides [25] . Besides its general role in being physical scaffold for the cellular constituents, the proper dynamics of ECM macromolecules is crucial for correct tissue morphogenesis [31] . There are numerous evidence indicating that deregulated composition and architecture of ECM macromolecules are involved in cellular malignant transformation and cancer progression [32] . For that purpose, premalignant OLP lesions were studied in comparison with OSCC and healthy oral mucosa. OLP is a chronic mucocutaneous autoimmune disease with already recognized potential for developing in OSCC [3, 33] , the most common form of head and neck cancer [34] . Although numerous studies have investigated pathology of OLP, the aetiology of its progression to OSCC is still unknown. To investigate a potential link between OLP and OSCC pathologies and contribution of deregulated ECM molecules to OLP malignant transformation, a mass spectrometry-based proteomics profiling of normal mucosa, OLP and OSCC tissues (and accompanied clinically unaltered tissues, respectively) was performed. With this approach, 55 extracellular matrix proteins were identified in analysed samples (Table 3) . Among them, six identified proteins were unique to OSCC including ladinin 1, eukaryotic initiation factor 4A-I, cathepsin D, cofilin-1, laminin subunit beta-3 and protein S100-A9 and three were unique to adjacent, histologically unaltered tissues including mimecan, suprabasin and cystatin-A. These findings are in line with previous studies which showed increased expression of the protease cathepsin D [32] , eukaryotic initiation factor 4A-I [35] , cofilin-1 [36] and S100A9 protein [37] in OSCC which was correlated with progression and invasion of tumour cells. In addition, decreased expression of small leucine-rich proteoglycan mimecan was previously reported in the oesophageal squamous cell carcinoma [38] . In OLP tissues, proteomics profiling revealed only two unique proteins, tenascin-X and Ras-related C3 botulinum toxin substrate 1. Tenascin-X was recently suggested as a novel diagnostic marker for ovarian cancer [39] and malignant mesothelioma [40] , so its identification only in OLP tissues implies its role in a malignant transformation of oral lichen planus as well. Similarly, Rasrelated C3 botulinum toxin substrate 1 can be associated with rapid epithelial differentiation and invasive properties of human cholesteatoma [41] and increased head and neck squamous cell carcinoma (HNSCC) cells invasion potential [42] . This also points to a potentially malignant nature of OLP. Interestingly, in normal mucosa tissues, ECM proteins fibulin-1 and asporin were identified (Table 3 ). This result is in line with literature data as diminished fibulin-1 expression has been previously reported in various malignant diseases [43] while asporin bears a tumour suppressive role in breast carcinoma [44] . Comparative analysis of identified extracellular matrix proteins between different groups of samples showed that 20 identified proteins were common to all groups of samples (Table 3) , for example the small leucine-rich proteoglycan lumican. Validation of mass spectrometry results for lumican by use of Western blot showed its expression in all analysed groups and significantly increased lumican expression was assessed for OSCC-T and OLP-T in comparison with their matched adjacent tissue and with normal mucosa tissues, respectively (Fig. 3) . Still, mass spectrometry analysis did not (1-3) ; OLP-AT-oral lichen planus corresponding histologically unaltered adjacent tissue (4-6); OLP-T-oral lichen planus tissue (7-9); OSCC-AToral squamous cell carcinoma corresponding tumour-free adjacent tissue (10) (11) (12) ; OSCC-T-oral squamous cell carcinoma tissue (13) (14) (15) reveal presence lumican in all analysed samples as shown by Western blot (Table 3 and Fig. 3 ). This might be a consequence of heavy glycosylation of proteoglycans lumican and biglycan [45] that is known to alter physico-chemical characteristics of peptides and which strongly influences ionization of glycoconjugates during the mass spectrometry analysis [46] . Lumican is constitutive protein expressed in many tissues [47, 48] , and has a role in maintenance of normal tissue integrity [49] . Moreover, recent evidence shows that elevated lumican expression has a negative impact on proper spatial organization of collagen fibres which facilitates local invasion in breast and pancreas cancer cell lines [50, 51] . Also, overexpression of lumican was associated with enhanced migration of colon cancer cell lines [52] and lumican overexpression correlated with cisplatin resistance in OSCC cell line and clinical HNSCC tissue specimens [53] . According to these results, it may be assumed that lumican expression assessed in OLP and OSCC tissues by Western blot analysis might reflect similar pathologies of OLP and OSCC and potentially contribute to malignant transformation of oral lichen planus lesions.
In addition, significantly elevated expression of the small leucine-rich proteoglycan biglycan was assessed in adjacent tissues of both OSCC-T and OLP-T groups (Fig. 3) . This result might be explained in the context of biglycan role in inflammatory processes which was well documented previously [54] . Indeed, in normal physiological conditions, biglycan has a role in maintenance of the extracellular matrix integrity. After tissue damage, biglycan is released by proteolytic cleavage from extracellular matrix and acts as an endogenous ligand for Toll-like receptors 2 and 4 on a surface of innate immune cells, i.e. macrophages [55] . Activation of Toll-like receptors induces strong immune response mediated by NfkB signalling pathway and production of proinflammatory cytokines occurs. This process promotes further infiltration of immune cells on a site of inflammation. It is well known that cytokines and growth factors released from the host immune, stromal and endothelial cells promote tumour cells growth and disease progression [56] . Tumour-associated inflammation is indeed a common event in HNSCC carcinogenesis as well [57] and it may be assumed that elevated biglycan expression in OLP and OSCC adjacent tissues contributes to enhanced infiltration of immune cells on a site of oral lichen planus and oral squamous cell carcinoma tissues and promotes malignant progression of both diseases.
The second aim of presented study was evaluation of the IGF2R and IGF2 role in OLP. The IGF2R is a developmentally regulated multifunctional transmembrane glycoprotein that lacks intracellular tyrosine kinase domain [58] . It is primarily a transport protein for M6P-bearing glycoproteins, but an increasing body of evidence implies its role in suppression of various malignant diseases [59, 60] . This may be due to IG2FR ability to inhibit cellular growth through negative regulation of IGF2 mitogenic activity [61] . Comparative semi-quantitative immunohistochemical analysis of IGF2 and IG2FR expression in samples of healthy oral mucosa, OLP and OSCC showed variable IGF2 immunoreactivity in all analysed samples, mainly moderate or weak intracellular immunostaining (Supplementary material). No statistical difference in IGF2 expression between analysed groups of samples was assessed. These results are in line with the study of Zhi et al. [57, 62] , where no statistically significant differences in IGF2 expression was observed in various forms of head and neck carcinoma (including squamous tumours of the larynx, oral cavity and pharynx) in comparison with adjacent tumour unaffected tissues. The authors suggested to analyse circulation levels of IGF1 and IGF2 growth factors in tumour tissues and in serum samples in future studies, which might provide more precise data in the IGF-2 role in malignant transformation. Similarly, IG2FR immunostaining in all analysed groups of samples was strong to weak and was observed mainly intracellularly. No significant differences in IG2FR expression was observed between analysed groups of samples, although an increased expression trend was observed in the control group vs. OLP and OSCC (Supplementary material). Similar observation was reported in the study of Mountzios et al. [13] , where association between IG2FR expression and clinicopathological parameters of patients that suffer from operable laryngeal squamous cell carcinoma was not observed. In addition, observed increased expression for IG2FR in normal healthy mucosa can be explained by literature data since IGF2R was found to be active in healthy mucosa where it acts as a tumour-suppressor. Its mutation is directly linked with increased risk of HNSCC [63] so herein presented result adds evidence on the precancerous potential of OLP and suggests that IGF2R axis might be included in the carcinogenesis of these potentially malignant oral lesions. Still, IGF2R expression should be evaluated in more details and on a larger cohort within prospective studies. Interestingly, a statistically significant difference between final IRS scores between IGF2 and IG2FR expression was determined for all analysed groups of samples (Supplementary material). This might point to the IG2FR role in regulation of extracellular IGF2 levels which can be considered as the indirect mechanism that influences cellular behaviour [61] . It is known that IGF-s including IGF2 are powerful mitogens whose expression is associated with various malignant diseases, and that observed expression level differences between IG2FR and IGF2 expression might be a consequence of the IG2FR antitumor role in OLP and OSCC where IG2FR acts as a negative regulator of IGF2 activity.
Conclusions
Proteomic profiling of OLP and OSCC by use of nano-LC-MS/MS revealed a number of altered ECM proteins and proteins connected with ECM signalization. In particular, small leucine-rich extracellular matrix proteoglycans biglycan and lumican were identified as important pathogenesis biomarkers of OLP that point to its malignant potential. Biglycan was indeed identified in tumour and adjacent tissue samples of patients diagnosed both with OLP and OSCC-T. Significantly elevated expression of biglycan in adjacent tissues of OSCC and OLP is probably due to enhanced infiltration of immune cells on a site of oral lichen planus and oral squamous cell carcinoma tissues where they promote malignant progression of both diseases. Lumican was identified in all analysed groups of samples but its significantly increased expression was found only in OSCC and OLP lesions in comparison with their matched, adjacent tissue and with normal mucosa tissues which points to its role as a potential contributor to malignant transformation of oral lichen planus lesions. At last, comparative semi-quantitative immunohistochemical analysis of IGF2 and IG2FR expression in samples of healthy oral mucosa, OLP and OSCC showed variable immunoreactivity in all analysed samples and no statistical differences in IGF2 and IGF2R expression between analysed groups of samples. However, a statistically significant difference between final IGF2 and IG2FR IRS scores was determined for all analysed groups of samples in favour to IGFR2. This result may further corroborate the IG2FR antitumor role in OLP and OSCC where it acts as a negative regulator of IGF2 activity.
